PROTAC AR Degrader-4 , CAS No.1351169-31-7

CAS: 1351169-31-7 Cat. No.: P1449533 Summenformel: C43H67N3O9 Molekulargewicht: 770.01
Zu bestellen verfügbar
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
Größe
Deutschland (EU)
USA*
Preis
Menge
1mg
P1449533-1mg
Auf Bestellung · 8–12 Wochen
Enter a quantity for the sizes you want to add.

Übersicht

PROTAC AR Degrader-4 comprises a IAP ligand binding group, a linker and an Androgen Receptor ( AR ) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers ( SNIPER s).

Spezifikationen

Storage
Store at -20°C
Verschickt in
Ice chest + Ice pads
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Aktionsart
INHIBITOR
Namen und Kennungen
Molekulargewicht
770.01

Erweiterte Daten

Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Lösungsrechner
Bewertungen

Kundenbewertungen

Application Protocols

Tested application types, dilutions, and positive controls must come from the product data. For this item, none are provided.

  • Tested applications (WB, IF, IHC, FC, cell-based assays): Not specified for this item; refer to CoA/Spec Sheet.
  • Recommended stock concentrations, dosing ranges, and incubation times: Not specified for this item; refer to CoA/Spec Sheet.
  • Positive control systems and assay readouts: Not specified for this item; refer to CoA/Spec Sheet.

Please consult the CoA/Spec Sheet and SDS for any available, lot-specific guidance. For general experimental design considerations with AR degraders, refer to the Reaction & Applications section.

Biological Roles

Context for AR biology and PROTAC-mediated degradation (general, literature-based; not item-specific):

  • Androgen receptor (AR): A ligand-activated transcription factor in the nuclear receptor superfamily. Upon androgen binding, AR dimerizes, translocates to the nucleus, and regulates genes via androgen-response elements.
  • Rationale for degradation vs inhibition: While antagonists block signaling, degradation removes the receptor, potentially attenuating both ligand-dependent and some ligand-independent activities. Degraders can reveal functions tied to receptor scaffolding vs transcriptional output.
  • Ubiquitin–proteasome system (UPS): PROTACs co-opt an E3 ligase to bring AR into proximity with the ubiquitination machinery, leading to K48-linked polyubiquitination and proteasomal turnover.
  • Kinetic pharmacology: Degraders act catalytically—multiple target molecules can be turned over per degrader molecule. Key parameters include DC50 (half-maximal degradation concentration), Dmax (maximal degradation), and t1/2,recovery upon washout.
  • Selectivity considerations: Ternary complex cooperativity can enhance selectivity beyond binary binding affinity. Off-target degradation may occur if the degrader mediates productive ternary complexes with unintended proteins.
  • Cell biology use-cases: Dissect AR’s role in transcriptional programs, chromatin interactions, and protein–protein interactions. Enables temporal control in pulse–chase designs and rescue experiments.

Note: No item-specific E3 ligase recruiter, binding affinity, or cellular potency data are provided in the Product Data for PROTAC AR Degrader-4. Verify details via CoA or primary literature before experimental design.

Buffer Applications

This compound is a bioactive small molecule, not a buffering agent.

Practical notes for assay buffers (general guidance; not item-specific):

  • Dosing into buffers: Prepare a DMSO stock, then add to the assay buffer under vigorous mixing to a low final DMSO percentage compatible with the biological system (often ≤0.1–0.2% v/v; confirm system tolerance).
  • Protein carriers: Inclusion of serum or BSA can reduce nonspecific adsorption and precipitation; pre-warm buffers to 25–37°C when appropriate to improve solubilization.
  • Common buffers: PBS, HBSS, or HEPES-buffered media for cellular assays; RIPA or mild lysis buffers for downstream Western blot quantification of AR levels.
  • Compatibility checks: Verify that buffer pH/ionic strength does not promote hydrolysis of labile linkages (amides/esters) and that supplemental components (e.g., cyclodextrins) do not sequester the compound unexpectedly.

Item-specific buffer compatibility, pH stability ranges, and solubility are not specified for this item; refer to CoA/Spec Sheet. For critical assays, perform a small pilot solubility/stability check in the exact buffer conditions to be used.

Green Alternatives

While green-chemistry considerations are less central for small-volume biological dosing, solvent and process choices during handling and any in-house synthesis/purification can reduce environmental impact.

Greener choices for dissolution/handling (general guidance; not item-specific):

  • Prefer DMSO over DMF/NMP for biological stock solutions due to lower hazard profiles and better biocompatibility at low % v/v.
  • Ethanol or aqueous PEG400 cosolvent systems can sometimes replace higher-toxicity aprotic solvents, provided stability and assay compatibility are maintained.
  • Minimize solvent volumes by preparing higher-concentration DMSO stocks where solubility allows, reducing waste.

Purification/workup considerations (if performing analog synthesis):

  • Replace dichloromethane (DCM) with EtOAc or 2‑MeTHF when chromatography performance permits.
  • Use water/EtOH/EtOAc biphasic systems in extractions to avoid chlorinated solvents.
  • Adopt reverse-phase aqueous chromatography (ACN/water or MeOH/water with volatile buffers) to cut halogenated solvent use.

Trade-offs:

  • Highly polar, high-MW degraders can challenge solubility in greener solvents; limited miscibility may necessitate DMSO or ACN. Balance EHS benefits with experimental robustness.

Sustainability practices:

  • Aliquoting to prevent degradation and reduce repeat preparations.
  • Closed, labeled waste streams for bioactive compounds to prevent environmental release.
  • Right-sizing experiments (microplate miniaturization) to reduce solvent and compound consumption.

These recommendations are general. For this specific item, no solvent or stability specifications are provided; consult the CoA/SDS for definitive guidance.

Pharmaceutical Uses

This product is supplied strictly for research use and is not intended for human or veterinary use, diagnostic procedures, or as an active pharmaceutical ingredient.

Formulation and development context (general, non-clinical):

  • Discovery-stage tool compound: Utilized in target validation, MoA studies, and pharmacology research to understand AR dependency. Data generated can guide medicinal chemistry but do not constitute clinical use.
  • Preformulation screening (in vitro): Solubility profiling in DMSO and biorelevant media, stability vs pH and serum esterases (if applicable), and nonspecific binding assessments (plasticware/protein) are common early evaluations.
  • Assay interference: Evaluate for aggregation or fluorescence interference when used in reporter assays; include DMSO and vehicle controls.
  • Regulatory status: No pharmacopeial monograph or GMP status is indicated. Any use beyond discovery research would require independent qualification and compliance workflows.

Item-specific information such as excipient compatibility, polymorphism, hygroscopicity, and stability-indicating methods is not specified for this item; refer to CoA/Spec Sheet. All experiments should be designed with appropriate quality controls and documentation in accordance with institutional policies.

Physical Properties

Item-specific physico-chemical data are not provided in the Product Data.

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point (Mp): Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point (Bp): Not applicable for typical PROTAC solids; item-specific value not provided.
  • Density / Refractive index: Not applicable (solid) or not specified.
  • LogP / LogD, pKa, UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Not specified for this item; refer to CoA/Spec Sheet.

General/literature characteristics for AR-targeting PROTACs (context only, not item-specific specifications):

  • Molecular size: Often 700–1200 Da with high polar surface area (PSA >100 Ų).
  • State: Typically a solid (amorphous or microcrystalline); hygroscopicity can vary.
  • Solubility profile: Frequently sparingly soluble in aqueous buffers; stock solutions commonly prepared in anhydrous DMSO and diluted into media or assay buffer with carrier proteins (e.g., serum) to mitigate precipitation.
  • Stability: PROTACs may exhibit sensitivity to hydrolysis in strongly acidic/basic media and potential amide/ester lability depending on linker chemistry. Light sensitivity varies; amber vials are commonly used as a precaution (literature practice).

Always verify item-specific values and handling characteristics on the CoA/Spec Sheet and SDS prior to use.

Quality and Grades

Item-specific quality metrics are limited in the provided data.

  • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.

Context and expectations for research-grade PROTACs:

  • Research grade (typical): Supplied for discovery biology and chemical biology. Purity is commonly established by HPLC/UPLC with UV or MS detection and identity confirmed by HRMS and/or NMR (literature/industry practice). Absence of stabilizers is typical for solid aliquots unless otherwise stated; if present, stabilizers would be disclosed on the CoA.
  • Assay impact of impurities: Trace synthetic impurities, residual solvents, or epimers can influence degradation kinetics and off-target effects. Review chromatograms and spectral data on the CoA to confirm suitability for quantitative biology (e.g., DC50/Dmax determination).
  • Batch-to-batch consistency: For tool compounds used in proteomics or HTS, confirm lot identity and potency in a small pilot experiment (e.g., short time-course Western blot for AR levels) to ensure reproducibility.
  • Documentation: Request the CoA/Spec Sheet for: assay purity, water and residual solvent content (if available), analytical methods, and storage guidance. If LC-MS response factors are provided, they can aid accurate dosing from DMSO stocks.

If a specific analytical grade (e.g., “Screening grade,” “>98% HPLC”) is required by your workflow, contact us to confirm availability prior to ordering.

Reaction and Applications

This product is supplied as a bioactive tool compound for targeted protein degradation studies, rather than as a synthetic reagent.

Research applications (general to AR-targeting PROTACs; not item-specific claims):

  • Chemical knockdown of AR: Induces formation of a ternary complex AR–PROTAC–E3, catalyzing polyubiquitination and proteasomal degradation. Useful for interrogating AR dependence in cellular phenotypes.
  • Orthogonal validation: Complements siRNA/CRISPR by permitting rapid, reversible protein depletion and enabling time‑resolved studies (on/off kinetics, recovery after washout).
  • Mechanistic controls: Employ proteasome inhibitors (e.g., MG132) or neddylation blockers (MLN4924) to confirm UPS dependence; use inactive analogs or warhead-only ligands as negative controls.
  • Proteomics & interactomics: Quantify on-target degradation and off-target effects via TMT/label-free MS; monitor ubiquitin linkage types and pathway engagement.
  • Phenotypic assays: Assess transcriptional outputs of AR signaling (reporter assays, qPCR of canonical targets) alongside protein abundance (WB/ELISA) to decouple binding antagonism vs degradation.

Practical considerations:

  • Hook effect: High concentrations can reduce ternary complex formation; perform dose-response spanning sub-nanomolar to micromolar to map DC50 and Dmax (literature practice).
  • Kinetics: Time-courses (e.g., 1–24 h) capture degradation onset and recovery upon washout.
  • Permeability: Consider efflux (e.g., P-gp) and solubility limits; verify intracellular exposure with LC-MS/MS where possible.

Note: No item-specific potency or application data are provided; consult literature and the CoA for any available characterization.

Reaction Conditions

As supplied, this compound is intended for use as a bioactive research tool, not as a reagent in chemical reactions. Therefore, no item-specific reaction conditions apply.

General conditions reported in the synthesis of PROTAC analogs (literature guidance; not specific to this item):

  • Amide couplings: DMF, DCM, or MeCN; HATU or EDCI with DIPEA/TEA; 0–25°C, 1–16 h. Monitor by LC-MS; typical isolated yields 50–90% per coupling step depending on sterics.
  • Carbamate/urea formation: CDI or DSC in DCM/THF; mild heating (25–50°C). Triphosgene or phosgene equivalents for symmetric/unsymmetric ureas.
  • Click chemistry (CuAAC): tBuOH/H2O (1:1) or DMF; CuSO4/sodium ascorbate; rt to 50°C, 1–6 h. Thorough copper removal is required before biological use.
  • Deprotections: Boc removal with TFA/DCM; CBz hydrogenolysis (H2, Pd/C, EtOH/EtOAc). Protect other sensitive motifs accordingly.
  • Purification: Reverse-phase prep-HPLC (water/ACN, volatile acid/base) to achieve high purity suitable for biology.

These conditions are provided solely as general reference for chemists synthesizing related molecules. No reaction or processing conditions are specified for the handling or modification of PROTAC AR Degrader-4 itself in the Product Data.

Safety and Handling

Follow standard precautions for laboratory handling of research chemicals.

Item-specific safety data (authoritative source: SDS):

  • GHS Classification / Pictograms / Signal Word / H-Statements: Not specified for this item; refer to SDS.

General laboratory guidance (not item-specific; align with institutional EHS):

  • PPE: Lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Use a fume hood for weighing, dissolution, and aliquoting—especially when handling DMSO stocks to prevent dermal exposure and aerosolization.
  • Incompatibilities: Avoid strong acids/bases and strong oxidizers that may degrade linker or functional groups; keep water out of anhydrous stock solutions.
  • Hygiene: Prevent contact with skin, eyes, and clothing. Wash thoroughly after handling. Do not pipette by mouth.
  • First aid overview: If inhaled—move to fresh air; if on skin—wash with soap and water; if in eyes—rinse cautiously with water for several minutes; if ingested—rinse mouth and seek medical attention. Always follow the SDS.
  • Spills & disposal: Absorb small spills with inert material and dispose as hazardous organic waste according to local regulations. Decontaminate surfaces with suitable solvent followed by detergent/water as permitted by the SDS.
  • Special risks (class guidance): As a bioactive small molecule designed to modulate intracellular protein homeostasis, handle as acutely potent at low concentrations. Avoid environmental release; label and segregate bioactive waste.

Consult the SDS for definitive hazard classification, exposure limits, and transport information.

Solvent Selection

Selection focuses on preparing concentrated, stable stocks and achieving homogeneous dosing in biological assays.

Item-specific solubility is not provided. The following are general, literature-informed practices for PROTACs:

  • Primary solvent: Anhydrous DMSO is typically preferred due to broad solvency for high-MW, polar heterobifunctionals.
  • Alternative/co-solvents: DMF, NMP (less preferred for cell work), and mixtures with ethanol or PEG400 can increase solubility; aqueous dilution should be gradual into buffered media with serum to suppress precipitation.
  • Aqueous media: Direct dissolution in water or PBS is commonly poor; instead, add DMSO stock to pre-warmed media under vortexing. Final DMSO is often kept ≤0.1–0.2% v/v in sensitive cell systems (laboratory practice; verify cell tolerance).
  • Adsorption minimization: Use low-binding plasticware or glass vials. Add a small amount of carrier protein (e.g., BSA in buffer) if nonspecific binding is suspected.

Comparison (general guidance):

  • DMSO: highest solvency, broadly cell-compatible at ≤0.1–0.5%.
  • DMF/NMP: strong solvency but reduced biocompatibility; reserve for chemical steps or low final percentages.
  • 2‑MeTHF/EtOAc/MeCN: limited for PROTAC stocks; useful for workup/purification, not for dosing.

Practical tips:

  • Prepare aliquoted stocks to avoid freeze–thaw; equilibrate to room temperature before opening to prevent moisture ingress.
  • Inspect for cloudiness after dilution; if present, sonication or slower addition may help. Always confirm homogeneity prior to dosing.
Storage and Reconstitution

Item-specific storage and shipping:

  • Storage Conditions: Store at −20°C (per Product Data).
  • Shipped In: Ice chest + ice pads (per Product Data).

Additional item-specific details (appearance, stabilizers, reconstitution solvent, concentration): Not specified for this item; refer to CoA/Spec Sheet.

General, literature-informed practices for PROTAC tool compounds (not item-specific specifications):

  • Reconstitution: Prepare stocks in dry, oxygen-free DMSO. Typical working stocks are in the 1–10 mM range, filtered through 0.22 μm PTFE if necessary to remove particulates. Verify actual concentration by UV or LC‑MS when quantitative accuracy is required.
  • Aliquoting: Dispense single-use aliquots in amber vials or low-bind tubes to avoid repeated freeze–thaw and light exposure.
  • Handling: Allow vials to reach room temperature before opening to minimize moisture condensation. Reseal promptly; purge headspace with inert gas when feasible.
  • Short-term stability: Keep thawed DMSO stocks at 2–8°C during use; return unused aliquots to −20°C promptly. Avoid multiple freeze–thaw cycles.
  • Aqueous dilutions: Prepare immediately before use. Inspect for precipitation; if observed, reduce concentration, warm gently, or adjust vehicle percentage while maintaining biological compatibility.

Always defer to the lot-specific CoA and SDS for definitive instructions on storage, stability, and reconstitution for PROTAC AR Degrader-4.

Structure and Identity

A heterobifunctional targeted protein degrader (TPD) designed to recruit an E3 ligase to the androgen receptor (AR), effecting ubiquitination and proteasomal clearance.

  • SKU: P1449533
  • Product Name: PROTAC AR Degrader-4
  • CAS: 1351169-31-7
  • Category: Small molecules and compound libraries (research use)
  • Research Use Note: For research use only

Item-specific identifiers:

  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general/literature description for AR-targeting PROTACs; not item-specific):

  • Modular architecture: (1) an AR-binding ligand (commonly derived from high-affinity AR antagonists/ligands), (2) a linker (aliphatic, PEG, or mixed), and (3) an E3 ligase recruiter (frequently CRBN or VHL ligands).
  • 2D description: Two pharmacophores connected by a flexible linker with multiple heteroatoms; numerous H-bond donors/acceptors; typically several rotatable bonds; generally no defined stereochemical centers in the linker but may contain stereochemistry within recruiter motifs.

Important note: The exact AR warhead, E3 recruiter, linker composition/length, and stereochemical configuration for PROTAC AR Degrader-4 are not disclosed in the provided Product Data. Consult the product CoA/Spec Sheet for definitive structure and identifiers.

Synthetic Utility

This product is a finished heterobifunctional degrader supplied for biological studies, not primarily as a building block. Nevertheless, understanding common synthetic features of AR-targeting PROTACs can aid analog design (general/literature guidance; not item-specific):

  • Retrosynthetic disconnection: Split into three modules—AR warhead, linker, and E3 ligase recruiter—each bearing orthogonally protected handles to control regiochemistry.
  • Coupling strategies: Amide bond formation (HATU/HOAt, HBTU, EDCI), carbamate/urea formation (triphosgene, CDI), and click-type reactions (CuAAC when azide/alkyne handles are present). Mitsunobu or carbonate linkages may appear in PEG-like linkers.
  • Protecting group management: Boc/CBz for amines, TBDPS/TBS for alcohols; ensure final global deprotection conditions are compatible with both pharmacophores.
  • Stereochemical integrity: VHL-type recruiters often include chiral hydroxyproline cores requiring mild conditions; epimerization control is critical.
  • Purification: Reverse-phase preparative HPLC is common, employing ACN/H2O with volatile modifiers (0.1% formic acid or ammonium bicarbonate, depending on ionization strategy).
  • Analytical confirmation: HRMS, 1H/13C NMR (often broad peaks due to conformational averaging), and LC-MS purity profiling across multiple wavelengths (220–280 nm) to detect aromatic and linker-associated chromophores.

Note: No synthetic handles, sequences, or analytical data are provided for PROTAC AR Degrader-4 in the Product Data. The above guidance is general and intended for chemists planning bespoke analogs.

Target Specificity

Only item-specific data may be presented here.

  • Intended target class (from name): Androgen receptor (AR) — inferred from product name; however, the Product Data do not provide confirmatory biochemical or cellular profiling.
  • E3 ligase recruiter, binding constants, DC50/Dmax, off-target profile, and species selectivity: Not specified for this item; refer to CoA/Spec Sheet.

Recommendations:

  • Verify target engagement via orthogonal assays (e.g., AR degradation by Western blot or mass spectrometry, and reversal with proteasome inhibition) before committing to large-scale studies.
  • If available, consult lot-specific CoA or published studies for quantitative selectivity metrics.

Note: No definitive target specificity data are provided in the Product Data for PROTAC AR Degrader-4.

Häufig gestellte Fragen

How should this product be stored?
Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 1351169-31-7, the molecular formula is C43H67N3O9, and the molecular weight is 770.01 g/mol.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Dürfen wir Sie über Rabattaktionen informieren?

Später erinnern

Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.

Hoppla! Benachrichtigungen sind deaktiviert.